With the emergency drug release program there is an evaluation process and we look at the data there. The data may be very limited; it's obviously not enough to issue a notice of compliance. That is why the drug comes in through the emergency drug release program.
There is also evaluation in the IND process. If there is an emerging disease where clearly there is enough data, then we have a case-by-case process whereby a company can come in and say that this is a priority review. Priority reviews of new drug submissions can be picked up very quickly and authorized or reviewed in a very timely manner.
So it really depends. We have a risk-managed approach within the system to allow those emerging drugs to come in very quickly when there are no other therapeutic options available.